Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ucb ADR (OP:UCBJY)

138.39 -3.21 (-2.27%)
Streaming Delayed Price Updated: 3:54 PM EST, Dec 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 17,824
Open 139.19
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 141.60
Today's Range 137.65 - 139.58
52wk Range 71.16 - 151.75
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
RFK Jr. Sued By Eli Lilly, Amgen Over Drug Discount Program ↗
Eli Lilly and Amgen are suing HHS over 340B certifications, claiming ineligible clinics cost them millions in lost revenue. 
Via Benzinga
Topics Lawsuit
News headline image
Biogen, UCB Take A Leap In Lupus With Promising Phase 3 Results ↗
UCB and Biogen's lupus candidate showed strong Phase 3 results, including fatigue improvement and higher remission versus standard care. 
Via Benzinga

Performance

YTD
+41.7%
+41.7%
1 Month
+4.0%
+4.0%
3 Month
+13.4%
+13.4%
6 Month
+47.3%
+47.3%
1 Year
+45.5%
+45.5%

More News

Read More
News headline image
Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study ↗
Via Benzinga
News headline image
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline ↗
Via Benzinga
Topics Government Supply Chain World Trade
News headline image
UCB's Rare Childhood Epilepsy Drug Scores FDA Approval ↗
Via Benzinga
News headline image
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed ↗
Via Benzinga
News headline image
Europe-Based UCB's Bimzelx Data Reveals Sustained Skin Clearance In Inflammatory Skin Disorders ↗
Via Benzinga
News headline image
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside ↗
Via Benzinga
News headline image
FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease ↗
Via Benzinga
News headline image
Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial ↗
Via Benzinga
News headline image
Longboard Pharmaceuticals Boasts High-Value Epilepsy Assets, Analyst Initiates Coverage ↗
Via Benzinga
News headline image
Week In Review: UCB Sells China Drug Portfolio To CBC For $680 Million ↗
Via Talk Markets
News headline image
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB ↗
Via Benzinga
News headline image
Belgium-Based Pharma Firm UCB To Offload China Neurology, Allergy Business For $680M To Asset Management Companies ↗
Via Benzinga
News headline image
There's Optimism Around Longboard Pharmaceuticals' Anti-Seizure Candidate: Analyst Boosts Price Target ↗
Via Benzinga
News headline image
Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst ↗
Via Benzinga
News headline image
Skin Disease Focused MoonLake Immunotherapeutics Poised To Outshine Rivals, Analyst Asserts ↗
Via Benzinga
News headline image
FDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in Adults ↗
Via Benzinga
News headline image
Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path ↗
Via Benzinga
News headline image
The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More ↗
Via Benzinga
News headline image
Biogen-Xbrane Enter License Agreement For Cimzia Referenced Biosimilar, Xcimzane ↗
Via Benzinga
News headline image
The Week Ahead In Biotech (Jan. 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, & More ↗
Via Talk Markets
News headline image
The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More ↗
Via Benzinga
News headline image
UCB's Bispecific Marks Phase 3 Win For Second Psoriatic Arthritis Study ↗
Via Benzinga
News headline image
ZGNX Stock: The $1.9B UCB Deal That Has Zogenix Shares Zooming Higher Today ↗
Via InvestorPlace

Frequently Asked Questions

Is Ucb ADR publicly traded?
Yes, Ucb ADR is publicly traded.
What exchange does Ucb ADR trade on?
Ucb ADR trades on the OTC Traded
What is the ticker symbol for Ucb ADR?
The ticker symbol for Ucb ADR is UCBJY on the OTC Traded
What is the current price of Ucb ADR?
The current price of Ucb ADR is 138.39
When was Ucb ADR last traded?
The last trade of Ucb ADR was at 12/12/25 03:54 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.